Metformin × body weight & composition

TrialArchives of internal medicine2009

Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.

Adriaan Kooy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Three numbers in the abstract

the abstract, start to end

prevented weight gain (mean weight gain, -3.07 kg [range, -3.85 to -2.28 kg]; P < .001), improved glycemic control (mean reduction in HbA(1c) level, 0.4% percentage point [95% CI, 0.55-0.25]; P < .001) (where CI indicates confidence interval), despite the aim of similar glycemic control in both groups, and reduced insulin requirements (mean reduction, 19.63 IU/d [95% CI, 24.91-14.36

← favours treatmentfavours comparator →
could be chance
Weight gainmetformin vs placebo, in null
−3.07−3.85 to −2.28
HbA(1c)metformin vs placebo, in null
−0.40−0.55 to −0.25
Insulin requirementsmetformin vs placebo, in null
−19.6−24.9 to −14.4
MetforminGlycemic controlBody weight & composition
1 / 3

160 papers cite itlatest 60 shown

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 19307526